

NGS cancer research panels, 11/14

November 2014—Agilent Technologies introduced ClearSeq AML, a next-generation cancer research panel that targets 48 selected exons in 20 of the most commonly mutated genes found in acute myeloid leukemia.

ClearSeq AML provides comprehensive coverage of mutations and 99.9 percent design coverage of targeted coding exons. Sample processing to mutation report is completed in less than 48 hours. Additional ClearSeq panels for cancer research will be released throughout the coming months.

[Agilent Technologies](#), 408-345-8886